Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.61 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | GAK | O14976 | 3/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 8/20 | 0.45 |
| ▸ | AURKA | O14965 | 7/20 | 0.45 |
| ▸ | MET | P08581 | 7/20 | 0.45 |
| ▸ | TEK | Q02763 | 7/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LYN | P07948 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | FGR | P09769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816424 | 0.83 | KDR (0.66) | KDRLCKAURKAMETTEK | |
| SCHEMBL2748014 | 0.81 | KDR (0.75) | KDREGFRGAKPDGFRALCK | |
| SCHEMBL2748802 | 0.76 | KDR (1.00) | KDRLCKAURKAMETTEK | |
| SCHEMBL4548961 | 0.76 | KDR (0.73) | KDREGFRLCKAURKAMET | |
| SCHEMBL4548960 | 0.75 | KDR (0.81) | KDRPDGFRALCKAURKAMET | |
| SCHEMBL2614562 | 0.74 | KDR (0.63) | KDREGFRGAKLCKAURKA | |
| SCHEMBL2614561 | 0.73 | KDR (0.74) | KDREGFRGAKLCKAURKA | |
| SCHEMBL2614553 | 0.71 | KDR (0.60) | KDRLCKAURKAMETTEK | |
| SCHEMBL2614552 | 0.70 | KDR (0.61) | KDRLCKAURKAMETTEK | |
| SCHEMBL2748016 | 0.69 | EGFR (0.60) | KDREGFRGAKPDGFRALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885EGFR 129/4885GAK 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.